Wegovy 1mg FlexTouch contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for chronic weight management in adults with obesity or overweight conditions accompanied by at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Semaglutide acts by mimicking the incretin hormone GLP-1, thereby enhancing glucose-dependent insulin secretion, suppressing glucagon release, and slowing gastric emptying, which collectively contribute to reduced appetite and caloric intake. Administered once weekly via subcutaneous injection using the pre-filled FlexTouch pen, Wegovy facilitates sustained plasma concentrations of semaglutide, optimizing therapeutic efficacy. Clinical trials have demonstrated significant weight reduction and improvement in metabolic parameters with Wegovy compared to placebo when combined with lifestyle interventions including diet and exercise. Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which tend to diminish over time. Caution is advised in patients with a history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. Wegovy should be used under medical supervision with appropriate monitoring to ensure safety and effectiveness in weight management.